Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Solasta Ventures

Investor type Venture Capital


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 26
Average round size
The average size of a deal this fund participated in
Portfolio companies 24
Rounds per year 8.67
Lead investments 0
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 6
Key employees Soon
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Life Science

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Solasta Ventures:
Typical Co-investors
Solasta Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Solasta Ventures:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
1st Course Capital California, Redwood City, United States
Africa's Talking Kenya, Nairobi, Nairobi Area
Asia Internet Holdings Central, Central Region, Singapore
Austin Technology Incubator Austin, Texas, United States
Break Off Capital -
Goldman Sachs Investment Partners New York, New York, United States
Ivanhoe Cambridge Canada, Montréal, Quebec
MapleWood Partners -
Northern Gulf Partners New York, New York, United States
OCT China, Fujian, Xiamen
Shanxi Dingxin Taihe China, Shaanxi, Xian Shi
Shengyin Investment China, Shanghai
Stafford Capital Partners Boston, Massachusetts, United States
Sunyard China, Hangzhou, Zhejiang
The Spruce House Partnership New York, New York, United States
Western Union Accelerator Powered by Techstars Colorado, Denver, United States
Zhuhai Shunlian -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation


$85M05 Jan 2023 Boston, Massachusetts, United States

Carisma Therapeutics

Health Care
Life Science
$30M21 Sep 2022 Philadelphia, Pennsylvania, United States

Tibit Communications

Information Technology
$30M23 Jun 2022 California, United States

Carbon Biosciences

Product Research
$38M21 Jun 2022 Lexington, Massachusetts, United States

Soul Machines

Artificial Intelligence
Information Technology
Machine Learning
Virtual Reality
$70M14 Feb 2022 Auckland, Auckland, New Zealand


Artificial Intelligence
Enterprise Software
Machine Learning
Software Engineering
$55M23 Nov 2021 San Francisco, California, United States

Immunitas Therapeutics

Life Science
$58M18 Aug 2021 Cambridge, Massachusetts, United States

Carisma Therapeutics

Health Care
Life Science
$12M01 Mar 2021 Philadelphia, Pennsylvania, United States

Carisma Therapeutics

Health Care
Life Science
$47M07 Jan 2021 Philadelphia, Pennsylvania, United States
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Solasta Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: